Remote Ischemic Preconditioning and Acute Kidney Injury in HTX
RIPCAT
Effect of Remote Ischemic Preconditioning on Acute Kidney Injury in Patients Undergoing Heart Transplantation
1 other identifier
interventional
40
1 country
1
Brief Summary
Postoperative Acute Kidney Injury (AKI) is a common complication after heart transplantation (HTX) affecting outcome of patients. Remote ischemic preconditioning (RIPC) is an intervention that showed positive effect on incidence of AKI in elective cardiac surgery. Effects of RIPC on AKI in HTX patients have not been investigated to date. Recently new biomarkers have been established, showing high sensitivity and specificity for AKI. Especially, Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) together with Tissue Inhibitor of Metalloproteinases-2 (TIMP-2), known as nephrocheck®, are diagnostic biomarkers in this context. Hence, the investigators want to conduct a randomized controlled feasibility and proof of concept trial to determine the effects of RIPC on AKI after HTX, defined/detected using postoperative urinary \[TIMP-2\]\*\[IGFBP-7\] concentration.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 4, 2022
CompletedFirst Posted
Study publicly available on registry
May 6, 2022
CompletedStudy Start
First participant enrolled
June 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2024
CompletedMay 1, 2024
April 1, 2024
1.9 years
May 4, 2022
April 30, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
postoperative TIMP2-IGFBP7 concentration
change in postoperative TIMP2-IGFBP7 concentration measured in urine of patients
first 48 hours after HTX (arrival ICU, 24 hours after HTX, 48 hours after HTX)
Secondary Outcomes (5)
Postoperative urinary biomarker concentration
first 48 hours after HTX (arrival ICU, 24 hours after HTX, 48 hours after HTX)
AKI and renal replacement therapy
first 72 hours
Major adverse kidney events (MAKE)
during 30 days after HTX
Major adverse cardiovascular events (MACE)
during 30 days after HTX
Days alive and out of hospital
during 30 days after HTX
Study Arms (2)
Sham RIPC
SHAM COMPARATORControl patients will be submitted to 3 cycles of sham RIPC. Each cycle of Sham RIPC consists of a pseudo ischemia of the left upper limb caused by inflating a blood pressure cuff to 20mmHg for 5 minutes followed by 5 minutes of reperfusion time.
RIPC
EXPERIMENTALPatients in the intervention group will be submitted to 3 cycles of RIPC. For each cycle of RIPC, a blood pressure cuff will be inflated at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time.
Interventions
For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
Eligibility Criteria
You may qualify if:
- \- adult patients (\>18 years) undergoing HTX
You may not qualify if:
- Acute myocardial infarction up to 7 days before surgery
- age younger than 18 years
- pre-existing AKI
- previous kidney transplantation
- chronic kidney disease with a glomerular filtration rate less than 30ml/min
- pregnancy
- peripheral vascular disease affecting the upper limbs
- hepato-renal syndrome
- drug therapy with sulfonamide or nicorandil
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Duesseldorf
Düsseldorf, North Rhine-Westphalia, 40225, Germany
Study Officials
- PRINCIPAL INVESTIGATOR
René M'Pembele, M.D.
Heinrich-Heine University, Duesseldorf
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 4, 2022
First Posted
May 6, 2022
Study Start
June 1, 2022
Primary Completion
April 30, 2024
Study Completion
April 30, 2024
Last Updated
May 1, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share